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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 300 (FGE.300): 
One cyclo-aliphatic amide from chemical group 33 1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate a flavouring substance in the Flavouring Group 
Evaluation 300 using the Procedure in Commission Regulation (EC) No 1565/2000. The substance 
was not considered to have genotoxic potential. The substance was evaluated through a stepwise 
approach (the Procedure) that integrates information on structure-activity relationships, intake from 
current uses, toxicological threshold of concern, and available data on metabolism and toxicity. The 
Panel concluded that for the substance [FL-no: 16.115] evaluated through the Procedure, no 
appropriate NOAEL was available and additional data are required. Besides the safety assessment of 
this flavouring substance, the specifications for the materials of commerce have also been considered. 
The composition of the stereoisomeric mixture has to be specified.  
 
© European Food Safety Authority, 2011 
SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate one flavouring substance in the 
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Flavouring Group Evaluation 300, (FGE.300), using the Procedure as referred to in the Commission 
Regulation (EC) No 1565/2000. The flavouring substance belongs to chemical group 33, Annex I of 
the Commission Regulation (EC) No 1565/2000. 
The substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115] 
possesses three chiral centres and has been presented with specification of the stereoisomeric 
composition. 
The substance is assigned into structural class III, according to the decision tree approach presented by 
Cramer et al., 1978. 
The substance in the present group has not been reported to occur naturally in food. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the flavouring substance in this group has a total intake in 
Europe of 3 microgram/capita/day, which is below the threshold of concern value for structural class 
III of 90 microgram/person/day. 
The results from the available limited genotoxicity studies do not raise a concern for genotoxicity and 
hence do not preclude the evaluation of the candidate substance in this FGE through the Procedure. 
From the data available it is not possible to conclude that the candidate substance in this group 
cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no. 16.115] would be 
metabolised to innocuous products at the reported levels of intake as flavouring substance. Therefore 
the substance was evaluated along the B-side of the Procedure. No toxicity study is available on the 
candidate or on the supporting substance that can provide an adequate NOAEL to be used in the 
Procedure, accordingly additional toxicity data are required for the candidate substance or a 
structurally related substance. 
When the estimated intake was based on the mTAMDI approach it was 960 microgram/person/day for 
this flavouring substance belonging to structural class III. The estimated intake for the candidate 
substance is above the threshold of concern of 90 microgram/person/day. Thus, for the flavouring 
substance considered in this Opinion the intake, estimated on the basis of the mTAMDI, exceed the 
relevant threshold for the structural class, to which the flavouring substance has been assigned. 
Therefore, for the substance more reliable exposure data is required. On the basis of such additional 
data, the flavouring substance should be reconsidered along the steps of the Procedure. Following this 
procedure additional toxicological data might become necessary. 
In order to determine whether the conclusion for the candidate substance can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Specifications including 
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purity criteria and identity for the materials of commerce have been provided for the flavouring 
substance. However, the composition of the stereoisomeric mixture has to be specified.   
In conclusion, for the flavouring substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-
cyclohexyl)-amide [FL-no: 16.115] the Panel considered that additional data are needed. Information 
on composition of isomers is missing. 
KEYWORDS 
Flavouring, safety, cyclo-aliphatic amide, FGE.300.   
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BACKGROUND 1 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 2 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 3 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 4 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 5 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2008/163/EC (EC, 6 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 7 
divided into 34 chemical groups. Substances within a group should have some metabolic and 8 
biological behaviour in common. 9 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 10 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 11 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 12 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 13 
2002b).  14 
After the completion of the evaluation programme the Union list of flavouring substances for use in or 15 
on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 16 
TERMS OF REFERENCE 17 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 18 
substances in the Register prior to their authorisation and inclusion in a Community list according to 19 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). In addition, the Commission requested 20 
EFSA to evaluate newly notified flavouring substances, where possible, before finalising the 21 
evaluation programme. 22 
In addition, in letter of 11 May 2009 the Commission requested EFSA to carry out a risk assessment 23 
on cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115] in 24 
accordance with Commission Regulation (EC) No 1565/2000 (EC, 2000a): 25 
“The European Commission requests the European Food Safety Authority to carry out a safety 26 
assessment on eightteen new flavouring substances in accordance with Commission Regulation (EC) 27 
No 1565/2000 (EC, 2000a), if possible by the end of the authorisation programme, if not within nine 28 
months from the finalisation of that programme.”   29 
The deadline of the Terms of Reference for cyclopropanecarboxylic acid (2-isopropyl-5-methyl-30 
cyclohexyl)-amide [FL-no: 16.115] was negotiated to 31 May 2011. 31 
The remaining 17 substances in the request of 11 May 2009 were evaluated in other FGEs. 32 
ASSESSMENT 33 
1. Presentation of the Substances in Flavouring Group Evaluation 300 34 
1.1. Description 35 
The present Flavouring Group Evaluation 300 (FGE.300), using the Procedure as referred to in the 36 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure - shown in schematic form 37 
in Annex I of this FGE), deals with one cyclo-aliphatic amide from chemical group 33, Annex I of 38 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). The flavouring substance, 39 
cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115] under 40 
consideration, as well as the chemical Register name, FLAVIS- (FL-), Chemical Abstract Service- 41 
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(CAS-), Council of Europe- (CoE-) and Flavor and Extract Manufactures Association- (FEMA-) 1 
numbers, structure and specifications, are listed in Table 1. 2 
The Panel is aware that there are several other amides in the Register considered in FGE.86 and 3 
FGE.94 and evaluated in FGE.304 which show partly structural similarities to the candidate substance. 4 
E.g. N-Ethyl-2-isopropyl-5-methylcyclohexane carboxamide [FL-no: 16.013] from FGE.86, N1-(2-5 
methoxy-4-methylbenzyl)-N2-(2-(pyridin-2-yl)ethyl)oxalamide [FL-no: 16.101], N-6 
[(Ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] and N-3,7-dimethyl-2,6-7 
octadienyl cyclopropylcarboxamide [FL-no: 16.095]) from FGE.94, all evaluated by the JECFA and 8 
considered by the Panel and  N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117] and N-9 
(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] evaluated by the Panel in 10 
FGE.304. Of these N-3,7-dimethyl-2,6-octadienyl cyclopropylcarboxamide [FL-no: 16.095] shows the 11 
best structural similarity with the candidate substance and will as the only one of the amides in the 12 
Register be used to support the evaluation of the candidate substance in the present FGE.  13 
The outcome of the Safety Evaluation is summarised in Table 2a. 14 
The hydrolysis products of the candidate amide are listed in Table 2b. 15 
The supporting substance is listed in Table 3, together with its evaluation status. 16 
1.2. Stereoisomers 17 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 18 
flavour may be different, they may have different chemical properties resulting in possible variability 19 
in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be 20 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 21 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 22 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 23 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 24 
substances with different configurations should have individual chemical names and codes (CAS 25 
number, FLAVIS number etc.). 26 
The candidate substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-27 
no: 16.115] possess three chiral centres and has been presented with specification of the stereoisomeric 28 
composition of two main isomers, however, as Industry has informed that further four other 29 
stereoisomers are present, the ratios of these isomers are needed. 30 
1.3. Natural Occurrence in Food 31 
The candidate substance [FL-no: 16.115] has not been reported to occur naturally in any food (TNO, 32 
2009). 33 
2. Specifications 34 
Purity criteria for the substance have been provided by the Flavour Industry (Flavour Industry, 2009h) 35 
(Table 1). 36 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 37 
2000a), this information is adequate for the candidate substance except the composition of the 38 
stereoisomeric mixture has to be specified. 39 
Flavouring Group Evaluation 300
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3. Intake Data 1 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 2 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 3 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 4 
population are consumers (SCF, 1999a). 5 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 6 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 7 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 8 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 9 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 10 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 11 
such cases, the human exposure thresholds below which exposures are not considered to present a 12 
safety concern might be exceeded. 13 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 14 
groups of consumers, the SCF recommended also taking into account the results of other intake 15 
assessments (SCF, 1999a). 16 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 17 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 18 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 19 
as a conservative estimate of the actual intake by most consumers because it is based on the 20 
assumption that the consumer regularly eats and drinks several food products containing the same 21 
flavouring substance at the upper use level. 22 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 23 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 24 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 25 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 26 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 27 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 28 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 29 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 30 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 31 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 32 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 33 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 34 
in food. 35 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 36 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 37 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 38 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 39 
The total annual volume of production of the candidate substance in the present Flavouring Group 40 
Evaluation (FGE.300) from use as flavouring substances in Europe has been reported to be 41 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
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approximately 25 kg (Flavour Industry, 2009h), and for the supporting substance to be approximately 1 
500 kg. The daily per capita intake for the candidate and supporting substances are 3.0 (Table 2a) and 2 
61 microgram (Table 3), respectively.  3 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 4 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 5 
is based on the approach used by SCF up to 1995 (SCF, 1995). 6 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 7 
day. 8 
For the candidate substance information on food categories and normal and maximum use levels5,6, 9 
were submitted by the Flavour Industry (Flavour Industry, 2009h). The candidate substance is used in 10 
flavoured food products divided into the food categories, outlined in Annex III of the Commission 11 
Regulation (EC) No 1565/2000 (EC, 2000a), as shown in Table 3.1. For the present calculation of 12 
mTAMDI, the reported normal use levels were used. In the case where different use levels were 13 
reported for different food categories the highest reported normal use level was used. 14 
Table 3.1 Use of Candidate Substance 
Food 
category 
Description Flavouring used  
01.0 Dairy products, excluding products of category 2 Yes 
02.0 Fats and oils, and fat emulsions (type water-in-oil) Yes 
03.0 Edible ices, including sherbet and sorbet No 
04.1 Processed fruits No 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
Yes 
05.0 Confectionery No 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses 
& legumes, excluding bakery 
No 
07.0 Bakery wares No 
08.0 Meat and meat products, including poultry and game Yes 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Yes 
10.0 Eggs and egg products Yes 
11.0 Sweeteners, including honey No 
12.0 Salts, spices, soups, sauces, salads, protein products etc. Yes 
13.0 Foodstuffs intended for particular nutritional uses No 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products Yes 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts No 
15.0 Ready-to-eat savouries Yes 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
No 
 15 
According to the Flavour Industry the normal use levels for the candidate substance is in the range of 16 
0.2-10 mg/kg food, and the maximum use levels are in the range of 1.7-20 mg/kg (Flavour Industry, 17 
2009h). 18 
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile 
of reported usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from 
figures derived from 12 model flavouring substances (EFFA, 2004e). 
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The mTAMDI value is 960 microgram/person/day for the candidate substance from structural class III 1 
(see Section 5).  2 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 3 
Section 6 and Annex II. 4 
4. Absorption, Distribution, Metabolism and Elimination 5 
Specific information regarding absorption, distribution, metabolism and excretion is not available for 6 
the candidate substance. 7 
Simple aliphatic amides, such as formamide, acetamide, propionamide, n-butyramide and n-8 
valeramide were reported to undergo hydrolysis in rabbits after oral administration. The extent of 9 
hydrolysis increased with increasing chain-length and ranged from 28 to 97 % of the dose. Complete 10 
hydrolysis was reported for phenylacetamide in rabbits. For the aliphatic amides increased hydrolysis 11 
was seen with increased chain-lengths following incubation with rabbit liver extracts and liver slices 12 
(Bray et al., 1949). 13 
Aliphatic and aromatic amides are expected to be partly metabolised to polar metabolites which are 14 
eliminated in the urine or bile (James, 1974; Schwen, 1982). Hydrolysis of the amide bond has been 15 
reported as a metabolic pathway for the amides dihydrocapsaicin and piperine in vivo in rats (Kawada 16 
and Iwai, 1985; Bhat & Chandrasekhara, 1987). 17 
Like other aliphatic and aromatic amides the candidate substance is anticipated to be absorbed from 18 
the gastrointestinal tract and at least partly hydrolysed. However, due to the lack of specific 19 
information on hydrolysis and metabolism and given the limited knowledge on hydrolysis of amides, 20 
it cannot be anticipated that the candidate substance is metabolised to innocuous products. 21 
For more detailed information, see Annex III. 22 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 23 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 24 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 25 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 26 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 27 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 28 
For the safety evaluation of the candidate substance from chemical group 33 the Procedure as outlined 29 
in Annex I was applied, based on the MSDI approach. The stepwise evaluation of the substance is 30 
summarised in Table 2a. 31 
Step 1 32 
The candidate substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-33 
no: 16.115] is classified according to the decision tree approach by Cramer et al. (Cramer et al., 1978) 34 
into structural class III. 35 
Step 2 36 
Step 2 requires consideration of the metabolism of the candidate substances. The candidate substance 37 
[FL-no: 16.116], cannot be anticipated to be metabolised to innocuous products and thus the 38 
evaluation proceeds via the B-side of the Procedure. 39 
Step B3 40 
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The estimated daily per capita intake of the candidate substance [FL-no: 16.115] is 3.0 microgram, 1 
which is below the threshold for its structural class of 90 microgram/person/day (class III). 2 
Accordingly, the evaluation of the substance proceeds to step B4 of the Procedure. 3 
Step B4 4 
No appropriate toxicity study could be identified to provide a No Observed Adverse Effect Level 5 
(NOAEL) for the candidate substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-6 
cyclohexyl)-amide [FL-no: 16.115]. For the supporting substance N-3,7-dimethyl-2,6-octadienyl 7 
cyclopropylcarboxamide [FL-no: 16.095] a NOAEL can be established from a 28-day feeding study in 8 
rats. However, the Panel does not accept the use of a 28-day study for deriving a NOAEL to be used in 9 
the Procedure. Accordingly, additional toxicity data are required. 10 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 11 
Approach 12 
The estimated intake for the candidate substance [FL-no: 16.115] assigned to structural class III, based 13 
on the mTAMDI, is 960 microgram/person/day, which is above the threshold of concern of 90 14 
microgram/person/day.  15 
Thus, for the candidate substance [FL-no: 16.115] further information is required. This would include 16 
more reliable intake data and then, if required, additional toxicological data. 17 
For comparison of the MSDI and mTAMDI values, see Table 6.1 18 
 19 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 






Threshold of concern 
(µg/person/day) 
16.115 Cyclopropanecarboxylic acid (2-isopropyl-5-
methyl-cyclohexyl)-amide 
3.0 960 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances 20 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 21 
many of the flavourings are metabolised through the same metabolic pathways and that the 22 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 23 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 24 
considered. As flavourings not included in this FGE may also be metabolised through the same 25 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 26 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 27 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 28 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 29 
summing the MSDI for individual substances. 30 
The combined intake of the candidate and supporting substance, both from structural class III, in 31 
Europe is estimated to be 64 micorgram/capita/day (3 and 61 microgram/capita/day, respectively). 32 
This value is below the threshold of concern for a structural class III substance of 90 33 
microgram/person/day. 34 
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8. Toxicity 1 
8.1. Acute Toxicity 2 
Data available for the candidate and supporting substances reports that the oral LD50 value, in rats, was 3 
greater than 2000 mg/kg body weight (bw). 4 
The acute toxicity data are summarised in Annex IV, Table IV.1. 5 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 6 
No data has been submitted, and no data on the candidate substance [FL-no: 16.115] was found when 7 
the open literature was searched. 8 
The supporting substance [FL-no: 16.095] has been tested in a 28-day study in rats.  9 
Abstract cited from the JECFA (JECFA, 2008b): 10 
“A 28-day dietary toxicity study was conducted in male and female CRL:CD (SD) IGS BR rats that 11 
were fed a diet containing N-3,7-dimethyl-2,6-octadienylcyclopropylcarboxamide at concentrations of 12 
0, 11, 110 or 1100 mg/kg. These dietary levels corresponded to measured daily intakes of 0, 0.92, 9 13 
and 92 mg/kg bw and 0, 0.98, 10 and 97 mg/kg bw for males and females, respectively. Whereas 5 14 
males and 5 females were included at the low- and mid-dose levels, the control and high-dose groups 15 
consisted of 10 males and 10 females.  16 
The test and control diets were presented to their respective groups on day 0 of the study. All the low- 17 
and mid-dose animals and half of the control and high-dose animals (non-recovery groups 1–8) were 18 
exposed to their test or control diet for at least 28 days, prior to necropsy on day 31. The remaining 19 
control and high-dose animals (groups 9–12) constituted the recovery group and were exposed to the 20 
test or control diet for 28 days, then were fed unsupplemented feed for an additional 14 days before 21 
necropsy on day 45. 22 
Prior to initial dosing and again on day 28, all rats were weighed and examined for visual impairment. 23 
In addition, all animals were observed daily for general health, symptoms of toxicity and behavioural 24 
changes. All rats were subjected to detailed weekly observation, including body weight and food 25 
consumption. Functional observational battery and motor activity tests were performed on test groups 26 
1–8 at week 4 post-initiation and on the recovery group animals at week 6. Blood for haematological 27 
and clinical biochemistry analysis was collected from groups 1–8 at week 5 and from groups 9–12 at 28 
week 7. Animals providing blood samples were fasted 24 hours prior to collection, and an urine 29 
sample was also collected from each animal. At the conclusion of the test period, gross necropsies 30 
were performed on all study rats, and selected organs and tissues were evaluated histologically in the 31 
control and high-dose groups. 32 
There were no test substance–related mortalities or clinical effects. A significant increase in food 33 
efficiency was reported during an unspecified measurement interval in low-dose males compared with 34 
controls; however, as this was transient and not dose related, it was not considered to be 35 
toxicologically significant. Urinalysis revealed no significant findings for any of the test groups as 36 
compared with controls. Haematology and clinical biochemistry revealed increases in mean cell 37 
volume in the low-dose and non–recovery group high-dose females. Low-dose females also exhibited 38 
an increase in mean cell haemoglobin compared with controls. Red blood cell counts for the 1100 39 
mg/kg recovery group females were statistically significantly increased compared with control values, 40 
but this occurred towards the end of the recovery period and therefore was not considered to be 41 
associated with the administration of the test material. Sorbitol dehydrogenase levels were increased in 42 
the 11 mg/kg and non–recovery group 1100 mg/kg males; however, this was attributed to the 43 
unusually low levels of sorbitol dehydrogenase in control rats (Everds, 2005; Merkel, 2005). 44 
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Compared with controls, significant increases in the organ to body weight and the organ to brain 1 
weight ratios of the thymus were reported in the high-dose non–recovery group males. In females, a 2 
significant increase in the organ to body weight ratio of the liver was reported in the high-dose non–3 
recovery group compared with controls. Macroscopic examination revealed gross lesions of the liver, 4 
lung, spleen, uterus, caecum, lymph nodes and kidneys in both sexes of animals and at varying dose 5 
levels; however, incidence of these lesions did not reach statistical significance compared with 6 
controls. Moreover, there were no underlying microscopic abnormalities associated with any of the 7 
lesions, or the microscopic changes were considered to be incidental and unrelated to the presence of 8 
the test material in the feed. Given the absence of any microscopic abnormalities related to the dietary 9 
administration of the test material, the relative organ weight variations were determined to be 10 
clinically irrelevant (Funk, 2005; Merkel, 2005).” 11 
8.3. Developmental / Reproductive Toxicity Studies 12 
No data has been submitted, and no data on the candidate substance [FL-no: 16.115] was found when 13 
the open literature was searched. 14 
8.4. Genotoxicity Studies 15 
In vitro data are available for both the candidate and the supporting substance.  16 
Candidate substance [FL-no: 16.115] 17 
No genotoxic potential was observed when cyclopropanecarboxylic acid (2-isopropyl-5-methyl-18 
cyclohexyl)-amide [FL-no: 16.115] was incubated with Salmonella typhimurium strains TA98, 19 
TA100, TA102, TA1535 and TA1537 with or without metabolic activation at concentrations up to 20 
1000 μg/plate in two separate experiments using the plate incorporation method and the preincubation 21 
method. The authors noted that in the plate incorporation method with and without metabolic 22 
activation, the 1000 μg/plate concentration of the candidate substance was cytotoxic to the bacteria 23 
(August, 2007). 24 
Supporting substance [FL-no: 16.095] 25 
N-3,7-Dimethyl-2,6-octadienyl cyclopropylcarboxamide [FL-no: 16.095] was tested in a bacterial 26 
reverse mutation test using S. typhimurium strains TA97a, TA98, TA100 and TA1535 and E. coli 27 
strain WP2uvrA with and without metabolic activation. It was concluded to be negative for the 28 
induction of mutagenicity (Next Century Incorporated, 2004). 29 
The results from the available limited genotoxicity studies do not raise a concern for genotoxicity and 30 
hence do not preclude the evaluation of the candidate substance in this FGE through the Procedure. 31 
Genotoxicity data are summaries in Annex IV, Table IV.4. 32 
9. Conclusions 33 
The candidate substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-34 
no: 16.115] possesses three chiral centres and has been presented with specification of the 35 
stereoisomeric composition. 36 
The substance is assigned into structural class III, according to the decision tree approach presented by 37 
Cramer et al., 1978. 38 
The substance in the present group has not been reported to occur naturally in food. 39 
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According to the default MSDI approach, the flavouring substance in this group has a total intake in 1 
Europe of 3 microgram/capita/day, which is below the threshold of concern value for structural class 2 
III of 90 microgram/person/day. 3 
The results from the available limited genotoxicity studies do not raise a concern for genotoxicity and 4 
hence do not preclude the evaluation of the candidate substance in this FGE through the Procedure. 5 
From the data available it is not possible to conclude that the candidate substance in this group 6 
cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no. 16.115] would be 7 
metabolised to innocuous products at the reported levels of intake as flavouring substance. Therefore 8 
the substance was evaluated along the B-side of the Procedure. No toxicity study is available on the 9 
candidate or on the supporting substance that can provide an adequate NOAEL to be used in the 10 
Procedure, accordingly additional toxicity data are required for the candidate substance or a 11 
structurally related substance. 12 
When the estimated intake was based on the mTAMDI approach it was 960 microgram/person/day for 13 
this flavouring substance belonging to structural class III. The estimated intake for the candidate 14 
substance is above the threshold of concern of 90 microgram/person/day. Thus, for the flavouring 15 
substance considered in this opinion the intake, estimated on the basis of the mTAMDI, exceed the 16 
relevant threshold for the structural class, to which the flavouring substance has been assigned. 17 
Therefore, for the substance more reliable exposure data is required. On the basis of such additional 18 
data, the flavouring substance should be reconsidered along the steps of the Procedure. Following this 19 
procedure additional toxicological data might become necessary. 20 
In order to determine whether the conclusion for the candidate substance can be applied to the 21 
materials of commerce, it is necessary to consider the available specifications. Specifications including 22 
purity criteria and identity for the materials of commerce have been provided for the flavouring 23 
substance. However, the composition of the stereoisomeric mixture has to be specified.   24 
In conclusion, for the flavouring substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-25 
cyclohexyl)-amide [FL-no: 16.115] the Panel considered that additional data are needed. Information 26 
on composition of isomers is missing.    27 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 300 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 300 







Solubility in ethanol 
2) 
Boiling point, °C 
3) 







































Two CASrn assigned 
958660-02-1 (1S,2S,5R) and 
958660-04-3 (1R,2R,5S). 
Min assay is sum of 
isomers: Two main isomers 
and four other 
stereoisomers. 
Composition of mixture to 
be specified. 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 




Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 





















B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required 7  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-
no 
EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 







O Not evaluated as a flavour - 
- 
 







Not evaluated as a flavour - 
- 
 
Not evaluated as a flavouring substance 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no Chemical name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 












No safety concern a) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2008b). 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC)No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products7 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous8 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
7 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
8 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?



















Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances.
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ANNEX II: USE LEVELS / MTAMDI 1 
II.1 Normal and Maximum Use Levels 2 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 3 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 4 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 5 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 6 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 7 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 8 
The “normal and maximum use levels” are provided by Industry for the candidate substances in the present 9 
flavouring group (Table II.1.2). 10 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.300 (Flavour 
Industry, 2009h) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 





































II.2 mTAMDI Calculations 11 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 12 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 13 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 14 
multiplied by the reported use levels in the different food categories and summed up.  15 
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
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Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 1 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 2 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 3 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 4 
following way (see Table II.2.2): 5 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 6 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 7 
(EC, 2000a) 8 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 9 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 10 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 11 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 12 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 13 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 14 
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The mTAMDI value (see Table II.2.3) is presented for the flavouring substance in the present flavouring 1 
group (Flavour Industry, 2009h). The mTAMDI value is only given for the highest reported normal use 2 
levels. 3 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
16.115 Cyclopropanecarboxylic acid (2-isopropyl-5-methyl-
cyclohexyl)-amide 
960 Class III 90 
 4 
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ANNEX III: METABOLISM 1 
III.1. Introduction 2 
The present FGE consists of one cyclo-aliphatic amide from chemical group 33: the candidate substance 3 
cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115].  4 
Specific information regarding absorption, distribution, metabolism and excretion is not available for the 5 
candidate substance. 6 
III.2. Absorption, Distribution, Metabolism and Excretion (ADME) 7 
The JECFA (2006) in its evaluation of a group of aliphatic and aromatic amines and amides used as 8 
flavouring substances evaluated the ADME of a few amides. 9 
The following text on absorption, distribution and elimination of amides is taken from the JECFA (JECFA, 10 
2006a):. 11 
“Studies on selected members of the group indicate that amides per se are rapidly absorbed and 12 
metabolised”. 13 
“Male Sprague-Dawley rats given a single oral dose of 4 mg/kg bw of N-(vanillyl)-[1-14C]nonamide 14 
(nonanyl 4-hydroxy-3-methoxybenzylamide) excreted 17.9%, 45.9% and 22.7% of the radiolabel in the 15 
urine, faeces and expired CO2, respectively, within 72 hours, although most of the radiolabel was excreted 16 
within the first 24 hours. Bile duct-cannulated rats excreted 11.4%, 3.7%, 11.7% and 65.1% of the radiolabel 17 
in the urine, faeces, expired CO2 and bile, respectively. In fasted rats, peak blood levels of radiolabel 18 
occurred 10 minutes after administration. By 72 hours after dosing, the highest concentration of radiolabel 19 
was found in fat, liver and adrenal gland. These results indicate that nonanyl 4-hydroxy-3-20 
methoxybenzylamide is rapidly absorbed and that appreciable quantities undergo enterohepatic circulation 21 
and partial conversion to CO2 (Schwen, 1982)”. 22 
“Groups of male albino Wistar rats were given piperine at a dose of 170 mg/kg bw by gavage or 85 mg/kg 23 
bw by intraperitoneal injection, and urine and faeces were collected every 24 hours for 12 days. Urine and 24 
faeces from rats fed a control diet for 10 days were collected for 3 days before treatment and used as control 25 
samples. When given by either route, about 3% of the unchanged dose was detected in faeces over 5 days, 26 
indicating that 97% of the piperine was absorbed. Peak excretion in the faeces occurred on day 1 after 27 
intraperitoneal injection and on 3 days after gavage. No unchanged piperine was detected in urine after 28 
administration by either route; however, there was increased excretion of conjugated glucuronides, sulphates 29 
and phenols, with maxima on days 1-4. Overall, 91-97% of the administered dose was accounted for. After 30 
treatment the animals were killed at various intervals, when blood was collected from the heart, and the liver, 31 
kidney, spleen and gut (stomach, small intestine, caecum and large intestine) were removed. By 30 minutes 32 
after ingestion of piperine, 29% was detected in the gut (22% in stomach and 6% in small intestine). By 48 33 
hours, 1% was detected in stomach, and 2-3% in the caecum and large intestine, indicating that 97% had 34 
been absorbed. A similar pattern was reported in rats intraperitoneally injected with piperine, although some 35 
of the values differed (data not reported). Between 1 and 10 hours after treatment, only traces of piperine 36 
administered by either route were detected in blood. Between 0.5 and 24 hours after treatment, 37 
intraperitoneally administered piperine was detected in the liver (2.12-0.4%) and kidney (0.04-0.2%). 38 
Similarly, orally administered piperine was detected in the liver (0.25-0.12%) and kidney (0.03-0.17%) up to 39 
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24 hours after treatment. No piperine was detected after 48 hours in any of the tissues examined (Bhat and 1 
Chandrasekhara, 1986a)”. 2 
“A group of male albino Wistar rats were given 175 mg/kg bw piperine by gavage. After 1 hour, some of the 3 
rats, including a group of untrated rats that served as controls, received a bile duct cannula, and bile was 4 
collected for 6 hours. Urine was collected from the remaining rats for 4 days and pooled, while urine 5 
collected for 4 days before dosing served as control samples. No unchanged piperine was detected in urine. 6 
Piperine was detected in the bile (about 1% of the original dose) within 6 hours, and various metabolites 7 
(piperonylic acid, vanillic acid and piperonyl alcohol) were excreated in urine (about 15.5% of the original 8 
dose) within 96 hours (Bhat & Chandrasekhara, 1987)”. 9 
“In rats given a single oral dose (not specified) of N-ethyl-para-menthane-[3-14C]-carboxamide (N-ethyl-2-10 
isopropyl-5-methylcyclohexanecarboxamide), 64.2% and 28.7% of the dose was excreted in urine and 11 
faeces, respectively, over 5 days. Almost 50% of the radioactivity was secreted into the bile within 2 days, 12 
most within 24 hours, indicating enterohepatic circulation of the parent compound or its metabolites. The 13 
peak plasma concentration (0.3% of the total dose) was reached within 1 hour. Subsequently, the compound 14 
was eliminated with a half-life of 11 hours. Whole-body autoradiography showed that most of the 15 
radioactivity was in the liver, kidneys and gastrointestinal tract. The results indicate that the substance was 16 
rapidly and extensively converted into more polar metabolites of unknown structure (James, 1974)”. 17 
The following text on metabolism, including hydrolysis, of amides is taken from JECFA (JECFA, 2006a): 18 
“The metabolic fate of N-ethyl-para-menthane-[3-14C]-carboxamide was examined in one male and one 19 
female dog given a single dose oral dose of 10 mg/kg bw. The substance was readily absorbed end rapidly 20 
eliminated in the urine (72% of the dose within the first 24 hours) and faeces (11% of the dose within 5 21 
days). No parent compound was detected in the urine. The main urinary metabolites were glucuronide or 22 
sulphate conjugates, whereas the faeces contained mainly unchanged compound. Radioactivity was detected 23 
(detection limit= 0.05 ppm) in the liver, adrenal glands (male only), testes and kidnet (female only) 5 days 24 
after treatment. Peak plasma levels were reached within 4 hours. Subsequently the compound was eliminated 25 
with a half-life of about 70 minutes. Plasma radioactivity was determined to consist mostly (> 90%) of 26 
metabolites of the test substance. About 70% was bound to plasma protein in vitro, but < 10% of the 27 
radioactivity was protein-bound in vivo. The author noted that rats metabolised the test substance to polar 28 
unconjugated metabolites, while dogs metabolised it to conjugates; however, both species metabolised it 29 
extensively and eliminated it rapidly (James, 1974)”. 30 
“These studies indicate that the amides in the group of flavouring agents are quickly absorbed, metabolised 31 
and excreted, mainly in urine but also partly in the faeces”. 32 
“Aliphatic amides have been reported to undergo limited hydrolysis. Extensive hydrolysis of aliphatic 33 
amides of various lengths was observed after incubation with rabbit liver extracts; however, hydrolysis was 34 
significantly slower for aliphatic amides with fewer than five or more than 10 carbons (Bray et al., 1949)”. 35 
“After administration of 1.5-5.0 g of acetamide or butyramide to rabbits, 62% of the dose of acetamide was 36 
recovered unchanged in the urine within 24 hours, while only 13% of the butyramide dose was recovered 37 
unchanged”. 38 
“Studies in which rats were given an oral dose (170 mg/kg bw) of piperine or dogs were given an oral dose 39 
(10 mg/kg bw) of N-ethyl-2-isopropyl-5-methylcyclohexanecarboxamide indicated that amide hydrolysis 40 
products are not major metabolites of these compounds (James, 1974; Bhat & Chandrasekhara, 1986a)”. 41 
“The metabolism of piperine was studied in groups of male albono Wistar rats given a dose of 170 mg/kg bw 42 
by gavage or 85 mg/kg bw by intraperitoneal injection. Urine and faeces were collected every 24 hours for 43 
12 days, while control urine and faeces samples were collected for 3 days from rats fed a control diet before 44 
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dosing. No unchanged piperine was detected in urine after exposure by either route; however, there was 1 
increased excretion of conjugated glucuronides, sulphates and phenols, with maximum excretion of all three 2 
on days 1-4. Demethylation of piperine was suggested by an increase in conjugated phenols. Over 8 days, 3 
about 36% of the gavage dose was excreted in urine as conjugated phenols and 62% as 4 
methylenedioxyphenyl metabolites. About 19% of the intraperitoneal dose was excreted as phenolics and 5 
about 72% as methylenedioxyphenyl derivatives (Bhat & Chandrasekhara, 1986a). The proposed pathways 6 
for the metabolism of piperine in rats involved in addition of amide hydrolysis to piperic acid, metabolic 7 
oxidative cleavage of the benzylic alkene function results in a series of vanilloyl and piperonyl derivatives, 8 
which are excreted free of in conjugated form, mainly in the urine (Bhat & Chandrasekhara, 1987)”. 9 
The panel, in addition to the studies identified by the  JECFA, also retrieved the following study by Kawada 10 
and Iwai (1985) in which the metabolism in rats of dihydrocapsaicin was investigated in vivo and in vitro: 11 
Within 48 hours after oral administration of dihydrocapsaicin (20 mg/kg bw) to male adult rats, unchanged 12 
dihydrocapsaicin and eight of its metabolites were identified in urine; i.e. dihydrocapsaicin (8.7 % of total 13 
dose), vanillylamine (4.7 %), vanillin (4.6 %), vanillyl alcohol (37.6 %) and vanillic acid (19.2 %) as free 14 
forms and/or their glucuronides. The proportions of free and and glucuronide metabolites in urine 14.5 % 15 
and 60.5 % of the total dose. Cell-free extracts of rat liver catalysed the hydrolysis of dihydrocapsaicin to 16 
vanillylamine and 8-methyl nonanoic acid. The former compound was further transformed to vanillin in situ. 17 
Dihydrocapsaicin-hydrolyzing enzyme activity was found in various organs of rats. The activity was located 18 
mainly in the liver (Kawada & Iwai, 1985). 19 
The Panel also had a further look at the study performed by Bray et al. (1949) and concluded that simple 20 
aliphatic amides, such as formamide, acetamide, propionamide, n-butyramide and n-valeramide were 21 
reported to undergo hydrolysis in rabbits after oral administration. The extent of hydrolysis increased with 22 
increasing chain-length and ranged from 28 to 97 % of the dose. Complete hydrolysis was reported for 23 
phenylacetamide in rabbits. For the aliphatic amides, increased hydrolysis was seen with increased chain-24 
lengths following incubation with rabbit liver extracts and liver slices (Bray et al., 1949). 25 
III.3. Summary and Conclusions 26 
Specific information regarding absorption, distribution, metabolism and excretion is not available for the 27 
candidate substance. 28 
Simple aliphatic amides, such as formamide, acetamide, propionamide, n-butyramide and n-valeramide were 29 
reported to undergo hydrolysis in rabbits after oral administration. The extent of hydrolysis increased with 30 
increasing chain-length and ranged from 28 to 97 % of the dose. Complete hydrolysis was reported for 31 
phenylacetamide in rabbits. For the aliphatic amides, increased hydrolysis was seen with increased chain-32 
lengths following incubation with rabbit liver extracts and liver slices (Bray et al., 1949). 33 
Aliphatic and aromatic amides are expected to be readily absorbed and partly metabolised to polar 34 
metabolites, which are eliminated in the urine or bile (James, 1974; Schwen, 1982). Hydrolysis of the amide 35 
bond has been reported as a metabolic pathway for the amides dihydrocapsaicin and piperine in vivo in rats 36 
(Kawada & Iwai, 1985; Bhat & Chandrasekhara, 1987). 37 
In summary, like other aliphatic and aromatic amides, the candidate substance is anticipated to be absorbed 38 
from the gastrointestinal tract and at least partly hydrolysed. However, due to the lack of specific information 39 
on hydrolysis and metabolism and given the limited knowledge on hydrolysis of amides in general, it cannot 40 
be anticipated that the candidate substance is metabolised to innocuous products.   41 
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ANNEX IV: TOXICITY 
 
Oral acute toxicity data are available for the candidate substance and the supporting substance of the present Flavouring Group Evaluation. 
TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  




Rat  F Gavage  ¾ 2000 (Vaeth, 2007)  
(N-3,7-Dimethyl-2,6- 
Octadienylcyclopropylcarboxamide [FL-no: 16.095]) 
Rat   > 2000 (Merkel, 2004)  
M = Male; F = Female; NR = Not reported. 
 
 
Subacute / subchronic / chronic / carcinogenic toxicity data are not available for the candidate substance but one study is available for the supporting 
substance (JECFA, 2008b).  
 
Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex2 
No./Group3 









5/the two mid doses 
10/control and high dose 
diet 0, 0.92, 9 and 92 (M) 
0, 0.98, 10 and 97 (F) 
28 (unsupplemented 
feed for add. 14 days) 
92 (Merkel, 2005b)  
 
TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
No Developmental and reproductive toxicity data are available neither for the candidate substance nor for structurally related substances of the present 
Flavouring Group Evaluation. 
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In vitro mutagenicity/genotoxicity data are available for the candidate substance of the present Flavouring Group Evaluation and for the one supporting 
substance. 
TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
Cyclopropanecarboxylic acid (2-
isopropyl-5-methyl-cyclohexyl)-
amide  [FL-no: 16.115]
Ames test S. typhimurium 
TA98; TA100; TA102; TA1535; TA1537 




Ames test S. typhimurium TA97a, TA98; TA100; 
TA1535 
E. Coli  WP2uvra 
Up to 5000 µg/plate Negative1 (Next Century Incorporated, 
2004)  
1 With and without metabolic activation. 
TABLE IV.5: GENOTOXICITY (IN VIVO) 
No In vivo mutagenicity/genotoxicity data are available neither for the candidate substance nor for structurally related substances of the present Flavouring 
Group Evaluation.  
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
ADME  Absorption, Distribution, Metabolism and Excretion 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50%; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
